Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung Cancer

BCD 1 Dan Pu
E 1 Jiewei Liu
E 1 Zhixi Li
EF 2 Jiang Zhu
AEF 1 Mei Hou

Corresponding Authors: Mei Hou, e-mail: houm118@msn.com; Jiang Zhu, e-mail: zhujiang1@medmail.com.cn

Source of support: Departmental sources

Background: This study aimed to explore the correlation between FGFR1 and clinical features, including survival analysis and the promotion of angiogenesis by fibroblast growth factor receptor 1 (FGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2). FGFR1 gene amplification has been found in non-small cell lung cancer (NSCLC). However, the prognostic value of FGFR1 and the correlation between FGFR1 and clinical features are still controversial.

Material/Methods: A total of 92 patients with NSCLC who underwent R0 resection between July 2006 and July 2008 were enrolled in the study. The expression of FGFR1, VEGFR2, and CD34 was detected by immunohistochemistry. The correlations between the aforementioned markers and the patients' clinical features were analyzed by the chi-square test. The impact factors of prognosis were evaluated by Cox regression analyses.

Results: The expression ratios of FGFR1 and VEGFR2 were 26.1% and 43.4%, respectively. The intensity of FGFR1 expression was related to VEGFR2 and histopathology. To some extent, the average microvessel density (MVD) had correlation to the expression of FGFR1 and VGEFR2. The pathological stages III-IV and high expression of FGFR1 were found to be independent prognostic factors.

Conclusions: The expression intensity of FGFR1 and VEGFR2 was associated with MVD, and the expression of FGFR1 is one of the independent prognostic indicators for NSCLC.

MeSH Keywords: Carcinoma, Non-Small-Cell Lung • Microvessels • Prognosis • Receptor, Fibroblast Growth Factor, Type 1 • Vascular Endothelial Growth Factor Receptor-2

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/899005
Background

Lung cancer is the leading cause of cancer-related death in China [1], of which 85% are non-small cell lung cancer (NSCLC). During the last decades, the treatments for advanced NSCLC were confined to platinum-based chemotherapy, with an unsatisfactory response rate of 30% [2]. Intensive studies on tumor-related aberrant signaling pathways have led to rapid development in the treatment of lung cancer. Medicines targeted at epidermal growth factor receptor (EGFR) gene mutation or anaplastic lymphoma kinase fusion gene increase the response rate to 65–80% [3,4], whereas tumor progression is still unavoidable eventually. With a median progression-free survival of about 10 months and a poor overall survival (OS), patients with advanced NSCLC need new therapeutic targets.

Fibroblast growth factor receptor 1 (FGFR1), a transmembrane tyrosine kinase receptor of fibroblast growth factors (FGFs), is encoded by FGFR1 gene (8p11-12). After combining with FGFs, FGFR ligand-dependent dimerization activates tyrosine kinase domains, resulting in the phosphorylation of intracellular tyrosine residues [5]. Phosphorylated tyrosine residues work as docking sites for adaptor proteins, such as Grb2, SOS protein, recruiting Ras-guanosine diphosphate (Ras-GDP), activating mitogen-activated protein kinase, protein kinase C, phosphatidylinositol 3-kinase/AKT pathway, and signal transducer and activator of transcription signaling pathways [6]. FGFRs regulate cell proliferation, differentiation, antiapoptosis, and angiogenesis [7]. The overexpression of FGFR1 was found in NSCLC and recognized as a novel therapeutic target. Its expression status, however, is less studied in the Chinese population. Although several meta-analyses have been reported, the correlation between the expression status of FGFR1 and clinical pathological features remains controversial [8–10]. This study focused on these issues and also studied the promotion of angiogenesis with VEGFR2, which is the main receptor of VEGF-A that plays an important role in neoangiogenesis [11]. The expression of VEGFR2 can be detected in a variety of tumor cells, including colorectal cancer [12], breast cancer [13], and non-small cell lung cancer [14]. The overexpression of VEGFs and VEGFR2 is related to tumor invasion and metastasis, mainly because of their effect on angiogenesis [15,16]. Studies have shown interaction between FGF-FGFR and VEGF-VEGFR signaling pathways. FGF can upregulate the expression of VEGF, FGFR, and VEGFR in epithelial cells, and VEGF can upregulate the expression of FGF [17,18]. It is widely known that tumor development and metastasis depend on neoangiogenesis [19]. Prior studies indicated that neoangiogenesis is essential in developing lung cancer, and microvesSEL density (MVD) is increased even in premalignant lesions and early-stage lung cancer [20,21]. In this retrospective study, the correlation between FGFR1 and clinical features was explored, including survival analysis and promotion of angiogenesis by FGFR1 and VEGFR2.

Material and Methods

Patients and specimens

This was a retrospective study. Ninety-two patients pathologically diagnosed with NSCLC, who received radical resection (pneumonectomy + lymph node dissection) in West China Hospital of Sichuan University from July 2006 to July 2008 were enrolled in the study. The exclusion criteria were as follows: received neo-adjuvant chemotherapy and/or radiotherapy; received EGFR tyrosine kinase inhibitors; had another kind of carcinoma; loss to follow-up; and histopathological specimens unavailable. The study was approved by the Hospital Ethics Committees, and all the patients enrolled gave informed consent. Follow-up data were obtained by telephone and/or outpatient department visits. The patients underwent chest computed tomography (CT) scan, abdomen CT scan, and brain magnetic resonance imaging, and also bone single-photon emission computed tomography if necessary, during periodic follow-up visit according to the National Comprehensive Cancer Network (NCCN) guideline. Staging was based on the NCCN guideline, and histological grading was evaluated according to the World Health Organization criteria. The clinical features included age, gender, stage, histological type, grade, lymph node status, smoking status, and postoperative adjuvant therapy. The primary endpoint was OS, and the secondary endpoint was recurrence-free survival (RFS).

Immunohistochemical staining

Formalin-fixed and paraffin-embedded surgical specimens were immunostained according to streptavidin-peroxidase protocol. The paraffin-embedded tissues were sliced up into slices of 4 μm. Then, after deparaffinization and antigen retrieval, the tissue sections were incubated with FGFR1 antibodies (monoclonal rabbit anti-human, 1:500, Cell Signaling Technology Co., Ltd, MA, USA), VEGFR2 antibodies (polyclonal rabbit anti-human, 1:100, Golden Bridge Biotechnology Co., Ltd, Beijing, China), and CD34 antibodies (monoclonal mouse anti-human, 1:100, Golden Bridge Biotechnology Co., Ltd, Beijing, China) at 4°C overnight. The patients underwent chest computed tomography (CT) scan, abdomen CT scan, and brain magnetic resonance imaging if necessary, during periodic follow-up visit according to the National Comprehensive Cancer Network (NCCN) guideline. Staging was based on the NCCN guideline, and histological grading was evaluated according to the World Health Organization criteria. The clinical features included age, gender, stage, histological type, grade, lymph node status, smoking status, and postoperative adjuvant therapy. The primary endpoint was OS, and the secondary endpoint was recurrence-free survival (RFS).

Evaluation criteria

Brownish-black or brown particles displayed in certain places were defined as a specific positive reaction. The weighted score,
evaluated in a semi-quantitative way, was calculated by multiplying the quantity score by staining intensity score, representing FGFR1 and VEGFR2 expression levels \[22,23\]. The quantity scores based on the percentage of stained cells were defined as follows: 0 for <5% cells stained; 1 for 5–25% cells stained; 2 for 26–50% cells stained; 3 for 51–75% cells stained; and 4 for ≥76% cells stained. The staining intensity was scored 0–3: 0 for no staining; 1 for pale yellow staining; 2 for brown staining; and 3 for brownish-black staining. Weighted score ≤1, 2–3, 4–6, or ≥7 was defined as negative, weak, moderate, or strong, respectively. For statistical analysis, the subgroups were finally dichotomized into high expression (moderate and strong) and low expression (negative and weak). CD34 was detected by immunostaining for MVD (24). The hot spots (intratumoral areas with a high density of CD34-positive vessels) were identified under low-power fields, while the CD34-positive vessels in hot spots were quantified under high-power fields case by case. The average value of 5 fields was defined as the MVD for each sample. All the specimens were evaluated by 2 pathologists independently.

**Statistical analysis**

SPSS 16.0 software (SPSS Inc., IL, USA) was used for statistical analysis. The correlations between the expression of FGFR1 and VEGFR2, MVD, and clinicopathological features were tested by chi-square test, t test, and Spearman’s rank correlation coefficient, respectively. Kaplan-Meier curve was used to analyze the correlation between the expression of FGFR1 and VEGFR2, MVD, and prognosis. Univariate and multivariate analyses were performed by Cox regression model. A P value less than 0.05 was considered to be statistically significant.

**Results**

**Clinical characteristics**

A total of 92 patients (70 males and 22 females) with a mean age of 58.5 (range 38–79) years were enrolled in the study. Classified by histological type, 49 patients had squamous lung cancer, 37 had adenocarcinoma, 4 had adenosquamous carcinoma, and 2 had large-cell lung cancer. Histologically, 54 samples were poorly differentiated, 36 moderately differentiated, and 2 well differentiated. According to the NCCN guideline of 2013, 25 patients were at stage I, 16 were at stage II, 42 were at stage III, and 9 were at stage IV. Moreover, 59 of all the patients were continuously smoking (defined as never quit or quit for less than 1 year), and 33 patients were nonsmokers or quit for more than 1 year.

**Expression of FGFR1, VEGFR2, and CD34 in NSCLC**

Both FGFR1 and VEGFR2 were mainly expressed in the cytoplasms (Figure 1A, 1B). In terms of FGFR1 expression, 25% (23/92) were negative, 48.9% (45/92) were weak, 18.5% (17/92) were moderate, and 7.6% (7/92) were strong. The high expression of FGFR1 was observed in 26.1% (24/92) of samples. Notably, the high expression rate of FGFR1 was significantly higher in squamous lung cancer than in adenocarcinoma (Table1. 36.7% vs. 16.2%, \(P=0.036\)). The high expression of FGFR1 was not correlated with smoking (23.7% vs. 30.3%, \(P=0.491\)), while in statistical analysis, we found that the expression rate (patients that had been tested to be positive, including weak, moderate and strong) of FGFR1 was significantly higher in smoking patients (84.7% vs. 60.6%, \(P=0.009\)). Moreover, 5.4% (5/92) of samples were VEGFR2 negative, 52.2% (48/92) were weak, 29.3% (27/92) were moderate, and 13% (12/92) were strong. The high expression of VEGFR2 was detected in 43.4% (39/92) of samples. Patients with lymph node metastasis (\(P=0.022\)) and those with tumor size more than 4 cm (\(P=0.001\)) had higher expression of VEGFR2. The high expression of FGFR1 and VEGFR2 was not correlated with the patients’ age, gender, smoking status, differentiation, and stage. Microvascular endothelial cells could be stained yellow or brownish by CD34 antibody (Figure 1C). The number of stained endothelial cells in a certain area was defined as MVD. In this study, the average MVD was 34.6. Patients with lymph node metastasis (37.5±10.7 vs. 31.0±10.3, \(P=0.004\)) and stages III–IV (36.9±10.7 vs. 31.7±10.5, \(P=0.024\)) presented with a significantly higher MVD in tumor tissues, while no correlation was found between MVD and gender, age, smoking status, histological type, and differentiation.

**Correlations among the expression of MVD, FGFR1, and VEGFR2**

MVD was significantly higher in patients with high expression of VEGFR2 than in patients with low expression of VEGFR2 (40.6±11.0 vs. 30.1±8.7, \(P<0.001\)), and a higher MVD was associated with the high expression of FGFR1 as well (43.1±10.1 vs. 31.5±9.6, \(P<0.001\)). The Spearman rank correlation analysis (Table 2) demonstrated that, to some extent, the expression intensity of VEGFR2 (\(r=0.224\), \(P=0.032\)) and FGFR1 (\(r=0.265\), \(P=0.011\)) was positively correlated with MVD. In addition, the expression levels of FGFR1 and VEGFR2 were significantly positively correlated (\(r=0.619\), \(P<0.001\)).

**Impact of FGFR1, VEGFR2, and MVD on prognosis**

With a total follow-up of 80 months, the patients with the high expression of FGFR1 presented with a significantly shorter OS (23.5 months vs. 39.8 months, \(P=0.043\)) and RFS (15.0 months vs. 28.0 months, \(P=0.043\)) than those with the low expression of FGFR1 (Figure 2A, 2B). The expression level of VEGFR2 showed no significant impact on the survival of patients with NSCLC. Notably, in squamous lung cancer, the OS in patients with the high expression of VEGFR2 was 32.5 months, which
was shorter than that in patients with the low expression (51.0 months, \( P = 0.028 \)) (Figure 2E). However, no significant difference was observed in the survival of patients with adenocarcinoma between high-expression and low-expression groups of VEGFR2 \( (P = 0.918) \) (Figure 2F). The analysis of the impact of MVD on OS and RFS is shown in Figure 2C and 2D. The RFS of patients with a high and a low value of MVD was 18.1 and 30.4 months \( (P = 0.010) \), respectively, while the OS in the low-MVD group was significantly longer than the OS in the high-MVD group (51.0 months vs. 32.5 months, \( P = 0.013 \)).

Univariate and multivariate analyses

All clinical and pathological features, including gender, age, smoking status, tumor size, differentiation, histological type, lymph node status, stage, adjuvant therapy, FGFR1 expression, VEGFR2 expression, and MVD value, were considered in the Cox regression model. The univariate analysis showed that tumor stage \( (P < 0.001) \), lymph node metastasis \( (P = 0.003) \), high expression of FGFR1 \( (P = 0.043) \), and high value of MVD \( (p = 0.013) \) in tumor tissue suggested shorter OS, while only stage III: hazard ratio [HR] 3.451, 95% confidence interval [CI]: 1.621–7.345, \( P = 0.001 \); stage IV: HR 39.207, 95% CI: 12.201–125.986, \( P < 0.001 \) and high expression of FGFR1 (HR 2.194, 95% CI: 1.232–3.908, \( P = 0.008 \)) remained independent.
Table 1. The correlation between the expression of FGFR1, VEGFR2, MVD, and clinicopathological features.

| Clinical features | Total | FGFR1 high expression | VEGFR2 high expression | MVD | Value | P |
|-------------------|-------|------------------------|------------------------|-----|-------|---|
| Gender            |       |                        |                        |     |       |   |
| Male              | 70    | 18 (25.7)              | 27 (38.6)              | 33.6±10.3 | 0.139 |
| Female            | 22    | 6 (27.3)               | 12 (54.5)              | 37.6±10.7 | 0.773 |
| Age (year)        |       |                        |                        |     |       |   |
| <60               | 51    | 10 (19.6)              | 18 (35.3)              | 33.8±11.2 | 0.497 |
| ≥60               | 41    | 14 (34.1)              | 21 (51.2)              | 35.4±10.8 | 0.216 |
| Smoke             |       |                        |                        |     |       |   |
| Yes               | 59    | 14 (23.7)              | 25 (42.4)              | 38.1±11.9 | 0.058 |
| No                | 33    | 10 (30.8)              | 14 (42.4)              | 33.1±10.6 | 0.139 |
| Tumor size        |       |                        |                        |     |       |   |
| <4 cm             | 47    | 11 (23.4)              | 12 (25.5)              | 35.9±10.5 | 0.261 |
| ≥4 cm             | 45    | 13 (28.9)              | 27 (60.0)              | 33.4±11.3 | 0.124 |
| Histopathology    |       |                        |                        |     |       |   |
| Squamous          | 49    | 18 (36.7)              | 21 (42.9)              | 34.0±11.9 | 0.380 |
| Adenocarcinoma    | 37    | 6 (16.2)               | 18 (48.6)              | 36.2±9.7 | 0.622 |
| Grade             |       |                        |                        |     |       |   |
| Poor              | 54    | 14 (25.9)              | 21 (38.9)              | 35.1±10.4 | 0.575 |
| Moderate/well     | 38    | 10 (26.3)              | 18 (47.4)              | 33.8±11.9 | 0.497 |
| Lymph node metastasis |     |                        |                        |     |       |   |
| Yes               | 51    | 12 (23.5)              | 27 (52.9)              | 37.5±10.7 | 0.004 |
| No                | 41    | 12 (29.3)              | 12 (29.3)              | 31.0±10.3 | 0.497 |
| Stage             |       |                        |                        |     |       |   |
| I–II              | 41    | 11 (26.8)              | 14 (34.1)              | 31.7±10.5 | 0.024 |
| III–IV            | 51    | 13 (25.5)              | 26 (51.0)              | 36.9±10.9 | 0.495 |
| Adjuvant therapy  |       |                        |                        |     |       |   |
| Yes               | 59    | 14 (23.7)              | 25 (42.4)              | 38.1±11.9 | 0.058 |
| No                | 23    | 8 (34.8)               | 11 (42.4)              | 35.0±10.9 | 0.216 |

Table 2. The correlation between FGFR1, VEGFR2, and MVD.

| VEGFR2 | MVD | FGFR1 |
|--------|-----|-------|
| Correlation coefficient | 1.00 | 0.224** | 0.619** |
| Sig. (2-tailed) | 0.032 | 0.011 | 0.001 |
| N | 92 | 92 | 92 |
| Correlation coefficient | 0.224* | 1.000 | 0.265* |
| Sig. (2-tailed) | 0.032 | 0.011 | 0.001 |
| N | 92 | 92 | 92 |
| Correlation coefficient | 0.619** | 0.265* | 1.000 |
| Sig. (2-tailed) | <0.001 | 0.011 | 0.001 |
| N | 92 | 92 | 92 |
Figure 2. Overall survival (OS) and recurrence-free survival (RFS) curves for patients with NSCLC. (A) The OS in FGFR1 low- and high-expression groups; a significant difference can be seen \(P=0.043\). (B) The RFS was significantly different between FGFR1 low- and high-expression groups \(P=0.043\). (C) The OS was significantly longer in the group with MVD <35 than in the group with MVD ≥35 \(P=0.013\). (D) The RFS was significantly longer in the group with MVD <35 than in the group with MVD ≥35 \(P=0.010\). (E) In squamous lung cancer, the OS was shorter in patients with the high expression of VEGFR2 than in the low-expression group \(51.0\) months, \(P=0.028\). (F) No significant difference was observed in the survival of patients with adenocarcinoma between the high- and low-expression groups of VEGFR2 \(P=0.918\).
Table 3. Univariate and multivariate analyses with regard to RFS and OS (n=92).

| Variable                        | Total No. | Univariate analysis | Multivariate Cox regression |
|---------------------------------|-----------|---------------------|-----------------------------|
|                                 |           | P                   | HR (95%CI)                  | P               |
| Gender                          |           |                     |                             |                 |
| Male                            | 70        | 0.830               |                             |                 |
| Female                          | 22        |                     |                             |                 |
| Age (year)                      |           |                     |                             |                 |
| <60                             | 51        | 0.662               |                             |                 |
| ≥60                             | 41        |                     |                             |                 |
| Smoke                           |           |                     |                             |                 |
| Yes                             | 59        | 0.742               |                             |                 |
| No                              | 33        |                     |                             |                 |
| Tumor size                      |           |                     |                             |                 |
| <4 cm                           | 47        | 0.095               |                             |                 |
| ≥4 cm                           | 45        |                     |                             |                 |
| Grade                           |           |                     |                             |                 |
| Poor                            | 54        | 0.536               |                             |                 |
| Moderate or well                | 38        |                     |                             |                 |
| Histopathology                  |           |                     |                             |                 |
| Squamous                        | 49        | 0.593               |                             |                 |
| Adenocarcinoma                  | 37        |                     |                             |                 |
| Lymph node metastasis           |           |                     |                             |                 |
| Yes                             | 51        | 0.003               |                             |                 |
| No                              | 41        |                     |                             |                 |
| Stage                           |           |                     |                             |                 |
| I                               | 25        |                     |                             |                 |
| II                              | 16        | <0.001              | 3.451 (1.621,7.345)         | 0.001           |
| III                             | 42        |                     |                             |                 |
| IV                              | 9         |                     | 39.207 (12.201,125.986)    | <0.001          |
| Adjuvant therapy                |           |                     |                             |                 |
| Yes                             | 69        | 0.708               | 0.492 (0.251,0.96)         | 0.039           |
| No                              | 23        |                     |                             |                 |
| FGFR1 expression                |           |                     |                             |                 |
| Low                             | 68        | 0.043               | 2.194 (1.232,3.908)        | 0.008           |
| High                            | 24        |                     |                             |                 |
| VEGFR2 expression               |           |                     |                             |                 |
| Low                             | 53        | 0.174               |                             |                 |
| High                            | 39        |                     |                             |                 |
| MVD                             |           |                     |                             |                 |
| <35                             | 47        | 0.013               |                             |                 |
| ≥35                             | 45        |                     |                             |                 |

HR – hazard risk; CI – confidence interval.
Figure 3. Overall survival (OS) curves for patients with NSCLC in different stages. (A) The OS in stage I; no significant difference can be seen ($P=0.093$). (B) The OS was not significantly different between FGFR1 low- and high-expression groups in stage II ($P=0.170$). (C) The OS was not significantly longer in the group with low FGFR1 expression in stage III ($P=0.269$). (D) The OS was not significantly longer in the group with low FGFR1 expression in stage IV ($P=0.088$). (E) The OS was significantly longer in the group with low FGFR1 expression in stage I–II ($P=0.044$). (F) No significant difference was observed in the survival of patients with low and high FGFR1 expression in stage III–IV ($P=0.253$).
risk factors of OS in multivariate analysis. Adjuvant chemotherapy was the protection factor for OS (HR 0.492, 95% CI: 0.251–0.964, \(P=0.039\)) (Table 3).

Considering that stage is universally thought to be the most important prognostic factor, stratified analysis based on stages was done (Figure 3). The OS was not significantly different between low- and high-expression of FGFR1 in stage I, II, III and IV, respectively, while when the patients with stage I and II were all taken into account, the OS was significantly longer in those with low FGFR1 expression than high FGFR1 expression (\(P=0.044\)). No significant difference was observed in the survival of patients with low and high FGFR1 expression in stage III-IV (\(P=0.253\)).

**Discussion**

Understanding the molecular alterations in lung cancer might provide better choices for targeted therapy. The malfunction of FGFR signaling pathway, mainly caused by the overexpression and/or mutation of receptor genes, was found in a variety of epithelial tumors [25–28], such as breast cancer, prostatic cancer, oral carcinoma, and gastric cancer. Both in vitro and in vivo experiments showed that the FGFR signal pathway played an important role in growth, survival, and migration of lung cancer cells, which could be blocked by FGFR tyrosine kinase inhibitor [29,30]. Previous studies compared the results between fluorescence in situ hybridization and immunohistochemistry (IHC) in detecting the overexpression of FGFR1, where no significant difference was detected between the 2 methods [31]. In this study, the expression of FGFR1 by IHC, and its correlation with VEGFR2 and MVD, was analyzed to evaluate its correlation with clinical features and the impact on prognosis.

According to previous reports, gene amplification of FGFR1 was about 16–20% in squamous lung cancer and 5% in adenocarcinoma. Inconsistently, researches from Weiss [32] and Schildhaus [33] showed no FGFR1 gene amplification in adenocarcinoma. Related researches were less conducted China. Several common histological types, such as squamous lung cancer, adenocarcinoma, large-cell lung cancer, and adeno-squamous carcinoma, were included in this study. The present study showed that 2 patients with large-cell lung cancer and 4 with adenosquamous carcinoma had FGFR1 negative or weak expression. FGFR1 expression was significantly higher in squamous lung cancer than in adenocarcinoma (36.7% vs. 16.2%, \(P=0.036\)), which was consistent with most previous reports [31,34]. The similarity between these results implicated no significant ethnic diversity in the FGFR1 status while large-scale researches are still in need. The expression rate of FGFR1 was slightly higher in this study than in previous reports, which might be due to different detection methods. For example, a newly published research using reverse transcription-polymerase chain reaction showed an extremely higher amplification rate of FGFR1 (41.5% in squamous lung cancer and 14.3% in nonsquamous lung cancer) than in any other researches. IHC is a widely used method in detecting the expression of specific proteins, which could test the expression of FGFR1. The standard method has not been identified yet. Zhang’s research showed that FGFR1 inhibitor induced tumor stasis or regression in the FGFR1-amplified NSCLC model [29]. This study demonstrated that FGFR1 was overexpressed in some NSCLCs, especially in squamous lung cancer in the Chinese population, suggesting that FGFR1 might be a potential target for targeted therapy and its inhibitor might be applied for the treatment of squamous lung cancer and a small part of adenocarcinoma harboring the high expression of FGFR1.

It is widely known that EGFR mutation frequently emerges in Asian female nonsmokers. Some studies suggested that smoking was also positively correlated with FGFR1 amplification [31], while some did not [34]. This study showed some differences, as the high expression of FGFR1 was not correlated with smoking (23.7% vs. 30.3%, \(P=0.491\)), while the expression rate of FGFR1 was significantly higher in smoking patients (84.7% vs. 60.6%, \(P=0.009\)). In conclusion, no correlation was found between high expression of FGFR1 and clinical characteristics such as age, gender, stage, grade, smoking status, and lymph node metastasis, suggesting no special predictive potential of these clinical characteristics for FGFR1 status in patients with NSCLC. Weiss [32] demonstrated that gene amplification of FGFR1 led to poor prognosis. Conversely, Trans [35] demonstrated that FGFR1 amplification suggested a longer survival. Inconsistent pathological types and different EGFR-TKI treatment status in analysis might explain the differing results. In this study, patients who had taken EFR-TKI after relapse were excluded, and multivariate analysis was used to identify the correlation between FGFR1 expression and clinical features. It showed that the high expression of FGFR1 was related to poor prognosis, which was consistent with the findings of Weiss’s research. However, in Weiss’s study, clinical pathological characteristics (e.g., stage, smoking status, and adjuvant chemotherapy) were not taken into consideration. The present study, using multivariate analysis (including gender, age, smoking status, tumor size, degree of differentiation, lymph node metastasis, stage, and adjuvant chemotherapy), demonstrated that patients with high expression of FGFR1 had shorter RFS and OS, suggesting that the high expression of FGFR1 was the independent prognostic indicator of NSCLC. We also took stage, the most important prognostic factor, into account. Although we found no significant difference in survival between low and high FGFR1 expression in stage I, II, III, and IV, when we combined the patients with stage I and II, the OS was significantly longer in those with low FGFR1 expression than high FGFR1 expression (\(P=0.044\)). No significant difference was observed
in the survival of patients with low- and high-FGFR1 expression in stage III–IV (P=0.253), indicating that the prognostic value could be more important in early stage of lung cancer. The small sample size may be why we did not get statistical significance in stage I and II separately.

VEGFR2 expression, mainly located in the cytoplasm, was found in most tumor tissues (94.6%) in this study, which was consistent with Decaussin's report [36]. The expression of VEGFR2 was not influenced by age, gender, smoking status, stage, or grade, but it was significantly higher in patients with lymph node metastasis (P=0.022) and/or tumor size more than 4 cm (P=0.001). Some studies suggested that the expression status of VEGFR2 was correlated with prognosis [37]. Seto's study [38], involving 60 postsurgery patients with stage I lung cancer, indicated that patients with VEGFR2 expression in tumor cells presented with poorer survival, while some other studies showed no correlation between VEGFR2 expression and prognosis [39]. A recent meta-analysis found no statistically significant effect of VEGFR2 expression on survival, but VEGFA/VEGFR2 co-expression had an influence on survival [40]. The differences might be caused by the diversity in stage, histological type, period of follow-up, and sample size between different studies. The present study showed no correlation between the expression statuses of VEGFR2 and RFS and OS in patients with NSCLC after surgery. The subgroup analysis, however, showed that in a subgroup of squamous lung cancer, patients with the high expression of VEGFR2 had shorter RFS and OS compared with the low-expression group (P=0.028; P=0.033), while this correlation was not found in adenocarcinoma. According to the literature, similar results were found in the Holzer’s study [41]. In other words, the expression status of VEGFR2 might play different roles in the prognosis of different histological types. In the meantime, it reflected indirectly that carcinomas with different histological types present with different biological characteristics, so that personalized treatment should be emphasized during treatment.

**References:**

1. Chen W, Zheng R, Zeng H et al: Annual report on status of cancer in China, 2011. Chin J Cancer Res, 2015; 27: 2–12
2. Smit EF, van Meerbeeck JP, Lianes P et al: Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J Clin Oncol, 2003; 21: 3909–17
3. Zhou C, Wu YL, Chen G et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011; 12: 735–42
4. Shaw AT, Kim DW, Nakagawa K et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 2013; 368: 2385–94
5. Eswarakumar VP, Lax I, Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev, 2005; 16: 139–49
6. Raja R, Palapeta SM, Sandhya VK et al: A Network Map of FGFR-1/FGFR signaling system. J Signal Transduct, 2014; 2014: 962962
7. Mohammadi M, Olsen SK, Ibrahimi DA: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev, 2005; 16: 107–37
8. Yang W, Yao YW, Zeng JL et al: Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: A meta-analysis. J Thorac Dis, 2014; 6: 803–9
9. Jiang T, Gao G, Fan G et al: FGFR1 amplification in lung squamous cell carcinoma: A systematic review with meta-analysis. Lung Cancer, 2015; 87: 1–7
10. Chang J, Liu X, Wang S et al: Prognostic value of FGFR gene amplification in patients with different types of cancer: A systematic review and meta-analysis. PloS One, 2014; 9: e105524
11. Cascone T, Troiani T, Morelli MP et al: Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol, 2006; 18: 151–55
12. Duff SE, Jezierska M, RosAD et al: Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy. Eur J Cancer, 2006; 42: 112–17

**Conclusions**

The high expression of FGFR1 existed in part of NSCLC (including squamous lung cancer and adenocarcinoma) and was the independent prognostic factor associated with poor prognosis, especially in early stages. The expression of FGFR1 and VEGFR2 was positively correlated, and both of them were associated with angiogenesis.

**Acknowledgment**

The authors would like to thank all their colleagues who participated in this study.

**Conflict of interest**

The authors declare no conflict of interest.
13. Dhakal HP, Naube B, Synnestvedt M et al: Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: Prognostic significance and relationship with markers for aggressiveness. Histopathology, 2012; 61: 350–64

14. Pomme G, Augustin F, Fieg M et al: Detailed assessment of microvascularity markers in non-small cell lung cancer reveals potentially clinically relevant characteristics. Virchows Arch, 2015; 467: 55–66

15. Claesson-Welsh L, Welsh M: VEGFA and tumour angiogenesis. J Intern Med, 2013; 273: 114–27

16. Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol, 2006; 39: 469–78

17. Tsuoda S, Nakamura T, Sakurai H, Saiki I: Fibroblast growth factor-2 induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A dependent neovascularization. Cancer Sci, 2007; 98: 541–48

18. Seghezzi G, Patel S, Ren CJ et al: Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol, 1998; 141: 1659–73

19. Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971; 285: 1182–86

20. Fontanini G, Calcinali A, Boldrini L et al: Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep, 1999; 6: 813–17

21. Keith RL, Miller YE, Gemmill RM et al: Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res, 2000; 6: 1616–25

22. Bonnesen B, Pappot H, Holmstav J, Skov BG: Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer, 2009; 66: 114–18

23. Behrens C, Lin HY, Lee JJ et al: Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res, 2008; 14: 6104–22

24. Bing Z, Jian-ru Y, Yao-quan J, Shi-feng C: Evaluation of angiogenesis in non-small cell lung carcinoma by CD34 immunohistochemistry. Cell Biochem Biophys, 2014; 70: 327–31

25. Turner N, Pearson A, Sharpe R et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res, 2010; 70: 2085–94

26. Kwabi-Addo B, Ozen M, Ittmann M: The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer, 2004; 11: 709–24

27. Freier K, Schweanen C, Stich C et al: Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol, 2007; 43: 60–66

28. Nakazawa K, Yashiro M, Hirakawa K: Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res, 2003; 63: 8848–52

29. Zhang J, Zhang L, Su X et al: Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res, 2012; 18: 6658–67

30. Marek L, Ware KE, Fritzschke A et al: Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small cell lung cancer cells. Mol Pharmacol, 2009; 75: 196–207

31. Kim HK, Kim DI, Kang DR et al: Fibroblast growth factor receptor I gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol, 2013; 31: 731–37

32. Weiss J, Sox ML, Seidel D et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med, 2010; 2: 62ra93

33. Schildhaus HU, Heukamp LC, Merkelbach-Bruse S et al: Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol, 2012; 25: 1473–80

34. Heist RS, Mino-Kenudson M, Sequist LV et al: FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol, 2012; 7: 1775–80

35. Tran TN, Selinger CJ, Kohonen-Corish MR et al: Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer, 2013; 81: 462–67

36. Decaussin M, Sartelet H, Robert C et al: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1 and VEGF-R2) in nonsmall cell lung carcinomas: Correlation with angiogenesis and survival. J Pathol, 1999; 188: 369–77

37. Carrillo de Santa Pau E, Arias FC, Caso Pelaez E et al: Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Cancer, 2009; 115: 1701–12

38. Seto T, Higashiyama M, Funai H et al: Prognostic value of expression of vascular endothelial growth factor and its receptors in nonsmall cell lung cancer. Lung Cancer, 2006; 53: 91–96

39. Dziadziouszko R, Chyczynski L, Jassem E, Jassem J: Expression of vascular endothelial growth factor (VEGF) and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer, 2009; 65(Suppl 2): 100–1

40. Zhong CL, Qiu C, Shen MX et al: Prognostic impact of elevation of vascular endothelial growth factor (VEGF) and its receptor FLK-1 in non-small cell lung cancer (NSCLC) – a preliminary report. Folia Histochim Cytobiol, 2001; 39(Suppl): 2: 100–1

41. Holzer TR, Fulford AD, Dedderman DM et al: Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung. PLoS One, 2013; 8: e80292

42. Cao R, Ji H, Feng N et al: Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA, 2012; 109: 15894–99